Italian pharmacy online: cialis senza ricetta medica in farmacia.
Microsoft word - flu recommendations_final2.docx
Distributed via the HAN Info Service
February 09, 2012, 15:00 EST
CDC Recommendations for Influenza Antiviral
A recent review of randomized clinical trial data for the influenza neuraminidase inhibitor antiviral medications, and two related commentaries, raised questions about the value of antiviral medications for the prevention and treatment of influenza. On February 7, 2012, the Centers for Disease Control and Prevention (CDC) posted a “Have You Heard?” piece in response. The CDC response states “After careful consideration of all available evidence, CDC guidance on the use of antiviral medications remains unchanged.” CDC continues to recommend the use of neuraminidase inhibitor antiviral drugs (oral oseltamivir and inhaled zanamivir) as an important adjunct in the prevention and treatment of influenza. These recommendations emphasize early antiviral treatment as soon as possible for patients who are severely ill and for those who are at greatest risk for complications from influenza. Patients who should receive early antiviral treatment include:
Hospitalized patients with suspected or confirmed influenza;
Persons with severe or progressive illness;
Outpatients who are at high risk for influenza complications (for example, young children, people 65 and older, pregnant women, and persons with certain underlying chronic medical conditions) (For a full list of people at high risk of influenza complications, see: http://www.cdc.gov/flu/about/disease/high_risk.htm); and
Persons with uncomplicated influenza who are not in a high risk group and who present within 48 hours of illness onset. These persons can be treated with antiviral medications based upon clinical judgment, because reviews of RCTs and observational studies have found consistent clinical benefit of early oseltamivir treatment in reducing the risk of lower respiratory tract complications such as those requiring antibiotics.
CDC estimates that influenza virus infections in the United States result in an average of more than 200,000 related hospitalizations and 3,300–49,000 deaths each year, depending upon the severity of the influenza season. Annual influenza vaccination of all persons aged 6 months and older is recommended, and is the best way to prevent influenza. However, available evidence for seasonal influenza and 2009 pandemic H1N1 consistently indicates that antiviral treatment, when initiated as soon as possible, can have clinical and public health benefit in reducing severe outcomes of influenza. Therefore, neuraminidase inhibitor antiviral medications continue to be recommended for treatment of influenza. The full CDC response is available at: http://www.cdc.gov/media/haveyouheard/stories/Influenza_antiviral.html. For a summary of CDC antiviral guidance for the 2011-2012 influenza season see: http://www.cdc.gov/flu/pdf/professionals/antivirals/clinician-antivirals-2011.pdf
For the full document outlining ACIP and CDC recommendations and references supporting the statements in the “Have You Heard,” CDC response, see “Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)” at: http://www.cdc.gov/mmwr/pdf/rr/rr6001.pdf
To read the review of randomized clinical trial data for the influenza neuraminidase inhibitor antiviral medications and related commentaries, see:
The Cochrane Library’s “Neuraminidase inhibitors for influenza: methods change, principles don’t” at: http://www.thecochranelibrary.com/details/editorial/1442857/Neuraminidase-inhibitors-for-influenza-methods-change-principles-dont.html
The British Medical Journal’s “Rethinking credible evidence synthesis” at: http://www.bmj.com/content/344/bmj.d7898
The British Medical Journal’s “Questions remain over safety and effectiveness of oseltamivir” at: http://www.bmj.com/content/344/bmj.e467
The Centers for Disease Control and Prevention (CDC) protects people's health and safety
by preventing and controlling diseases and injuries; enhances health decisions by providing
credible information on critical health issues; and promotes healthy living through strong
partnerships with local, national and international organizations.
DEPARTMENT OF HEALTH AND HUMAN SERVICES
____________________________________________________________________________________ Categories of Health Alert messages: Health Alert
conveys the highest level of importance; warrants immediate action or attention.
Health Advisory provides important information for a specific incident or situation; may not require immediate action. Health Update provides updated information regarding an incident or situation; unlikely to require immediate action. HAN InfoService provides general public health information; unlikely to require immediate action.
##This message was distributed to state and local health officers, public information officers,
epidemiologists and HAN coordinators, as well as clinician organizations.##
You have received this message based upon the information contained within our emergency notification data base. If you have a different or additional e-mail or fax address that you would like us to use, please contact your state-based Health Alert Network program at your state or local health department.
Canadian Diagnosis and Management Guidelines FM-CFS CANADA Canadian Diagnosis and Management GuidelinesFM-CFS Canada thanks Dr. Anil K. Jain and Dr. for their review of this Guide,which is based on their work with an International Panel of Experts that developed a widelyrespected Clinical Case Definition, Diagnostic and Treatment Protocol for MyalgicEncephalomyelitis/Chronic Fatigue Syndro
International School of Liquid Crystals 10th Workshop COMPUTATIONAL METHODS FOR POLYMERS AND LIQUID CRYSTALLINE POLYMERS A NATO Advanced Research Workshop Erice (TP), Centre E. Majorana, July 16 - 22, 2003 Directors of the Workshop: P. Pasini, S. Žumer INVITED TALKS G. Allegra G. Allegra J. H.R. Clarke and W. den Otter J. H.R. Clarke, A. Sunaidi